← ANALYST RATINGS · TIPRANKS
Amneal Pharmaceuticals (AMRX): analyst forecast and price target
Analyst consensus
Strong Buy6 Buy0 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $22.00, the highest $27.00, the lowest $17.00. The average is +14.7% from the last price of $19.18.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Les Sulewski★★★★★★★★★★#1947 · hits 51% · avg +11.5% | Truist Financial | $27.00 | Buy | +40.8% | Initiated | 23.09.26on TipRanks Sep 29 21:02 | −0.2%next day +2.5% · 5 days +4.9% | ↗ |
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $19.50 → $22.00+12.8% | Hold | +14.7% | Reiterated | 22.09.26on TipRanks 16:05 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $19.00 → $21.50+13.2% | Hold | +12.1% | Reiterated | 22.09.26on TipRanks 16:05 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $19.00 → $21.00+10.5% | Hold | +9.5% | Reiterated | 22.09.26on TipRanks 16:05 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $18.50 → $21.00+13.5% | Hold | +9.5% | Reiterated | 22.09.26on TipRanks 16:05 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $20.00 → $22.50+12.5% | Buy | +17.3% | Upgrade | 22.09.26on TipRanks 16:05 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $19.00 → $21.00+10.5% | Hold | +9.5% | Reiterated | 22.09.26on TipRanks 16:05 | — | |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | — | Buy | — | Reiterated | 21.09.26on TipRanks 07:07 | +6.2%next day −3.3% · 5 days +2.7% | ↗ |
| Glen Santangelo★★★★★★★★★★#2956 · hits 52% · avg +4.5% | Barclays | $20.00 | Buy | +4.3% | Reiterated | 21.09.26on TipRanks 04:15 | +6.2%next day −3.3% · 5 days +2.7% | ↗ |
| Daniel Clark★★★★★★★★★★#3492 · hits 65% · avg +17.4% | Leerink Partners | $23.00 | Buy | +19.9% | Reiterated | 17.09.26on TipRanks 07:50 | 0.0%next day +2.2% · 5 days +7.5% | ↗ |
| Matthew Dellatorre★★★★★★★★★★#1038 · hits 100% · avg +60.3% | Goldman Sachs | $19.00 → $21.00+10.5% | Buy | +9.5% | Reiterated | 10.08.26on TipRanks 07:35 | −1.4%next day −4.0% · 5 days +3.1% | ↗ |
| Ashwani Verma★★★★★★★★★★#1305 · hits 60% · avg +13.4% | UBS | $23.00 → $25.00+8.7% | Buy | +30.3% | Reiterated | 03.08.26on TipRanks 07:35 | +1.5%next day −3.8% · 5 days −7.2% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $17.00 | Buy | −11.4% | Reiterated | 20.07.26on TipRanks Jul 24 05:08 | −1.8%next day +2.6% · 5 days +3.8% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Amneal Pharmaceuticals
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $22.17 at a price of $20.14 (+10.1%); now: $22.17 at $19.18 (+15.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 10 | 9 | 11 | 11 | 12 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.23 (from $0.20 to $0.28). Last quarter: $0.30.
Sales
Next quarter’s sales estimate — $812M (from $792M to $830M). Last quarter: $796M.
Best top-analyst consensus in the sector · Healthcare
About Amneal Pharmaceuticals
- CEO: Chirag K. Patel
- Employees: 8,700
- 400 Crossing Boulevard, Bridgewater, NJ, 08807, US
- www.amneal.com
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party
Data from the stock’s TipRanks forecast page, read 15 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗